Progression of visual field loss (worsening of one or more stages, accordingto the Glaucoma Staging System‐2) (at 12 months) · participants with primary angle‐closure glaucoma
Phacoemulsification probably leads to lower progression of visual field loss (worsening of one or more stages,… compared with laser peripheral iridotomy (moderate certainty).
1 finding from 1 review
OR 0.35 [0.13, 0.91]
Studies not reported
Moderate
Cramp severity (0 to 10 VAS; higher = more pain) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Functional impairment · adults with post‐traumatic stress and CMDs
1 finding from 1 review
Treatment failure (development of more severe signs and symptoms by the end of treatment) · children, aged 2 to 59 months, with WHO‐defined non‐severe pneumonia and wheeze
Antibiotic therapy may leads to lower treatment failure (development of more severe signs and symptoms by… compared with placebo compared to placebo (low certainty).
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Perception of coping · parents and carers of children with complex needs
1 finding from 1 review
Family functioning · parents and carers of children with complex needs
1 finding from 1 review
Perceived social support · parents and carers of children with complex needs
1 finding from 1 review
Confidence and skill at navigating medical services · parents and carers of children with complex needs
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes reduction in seizure frequency of 50% or more compared with phenobarbital (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with AD and epileptic seizures
It is very uncertain whether lamotrigine changes reduction in seizure frequency of 50% or more compared with phenobarbital (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes reduction in seizure frequency of 50% or more compared with lamotrigine (very low certainty).
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
1 finding from 1 review
Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
It is very uncertain whether early active flexion plus controlled passive exercise regimen changes adverse events: participants incurring one or more adverse events compared with early controlled passive exercise regimen (very low certainty).
1 finding from 1 review
Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · schoolchildren with CSOM
It is very uncertain whether systemic antibiotics changes resolution of ear discharge (4 weeks or more) ‐ measured at 3 to 4… compared with no treatment or placebo on top of topical antiseptics (very low certainty).
1 finding from 1 review